Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Notice of Preliminary Results


RNS Number : 1623G
Evgen Pharma PLC
25 May 2017
 

 

For immediate release

 25 May 2017

 

 

 

 

 

 

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Notice of Preliminary Results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2017 on Tuesday 13 June 2017.

A meeting for analysts will be held at 11.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further information, or to register attendance, please contact Buchanan at the contact details below.

 

Enquiries:

 

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

c/o +44 (0) 20 7466 5000

 

 

 

Buchanan

Mark Court, Sophie Cowles, Stephanie Watson

+44 (0) 20 7466 5000

 

 

 

Northland Capital Partners Limited

Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)

John Howes and Rob Rees (Corporate Broking)

+44 (0) 20 3861 6625

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORQZLFLDEFXBBB



Evgen Pharma Timeline

Article
October 21 2015

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use